CL2016000190A1 - Polipéptidos cíclicos para el tratamiento de la insuficiencia cardiaca. - Google Patents
Polipéptidos cíclicos para el tratamiento de la insuficiencia cardiaca.Info
- Publication number
- CL2016000190A1 CL2016000190A1 CL2016000190A CL2016000190A CL2016000190A1 CL 2016000190 A1 CL2016000190 A1 CL 2016000190A1 CL 2016000190 A CL2016000190 A CL 2016000190A CL 2016000190 A CL2016000190 A CL 2016000190A CL 2016000190 A1 CL2016000190 A1 CL 2016000190A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment
- heart failure
- cyclic polypeptides
- polypeptides
- cyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361858263P | 2013-07-25 | 2013-07-25 | |
US201462015854P | 2014-06-23 | 2014-06-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2016000190A1 true CL2016000190A1 (es) | 2016-07-08 |
Family
ID=51263584
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2016000190A CL2016000190A1 (es) | 2013-07-25 | 2016-01-25 | Polipéptidos cíclicos para el tratamiento de la insuficiencia cardiaca. |
Country Status (24)
Country | Link |
---|---|
US (3) | US9266925B2 (es) |
EP (1) | EP3024845A1 (es) |
JP (1) | JP6501775B2 (es) |
KR (1) | KR20160031551A (es) |
CN (1) | CN105612172A (es) |
AP (1) | AP2016009021A0 (es) |
AU (1) | AU2014293386B2 (es) |
BR (1) | BR112016001542A2 (es) |
CA (1) | CA2918074A1 (es) |
CL (1) | CL2016000190A1 (es) |
CR (1) | CR20160048A (es) |
CU (1) | CU20160013A7 (es) |
EA (1) | EA201690278A1 (es) |
HK (1) | HK1218298A1 (es) |
IL (1) | IL243682A0 (es) |
MX (1) | MX2016001020A (es) |
PE (1) | PE20160878A1 (es) |
PH (1) | PH12016500104A1 (es) |
SG (1) | SG11201600211XA (es) |
SV (1) | SV2016005145A (es) |
TN (1) | TN2016000031A1 (es) |
TW (1) | TW201536814A (es) |
UY (1) | UY35670A (es) |
WO (1) | WO2015013168A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8673848B2 (en) | 2012-01-27 | 2014-03-18 | Novartis Ag | Synthetic apelin mimetics for the treatment of heart failure |
UY35144A (es) * | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
SG11201600208RA (en) | 2013-07-25 | 2016-02-26 | Novartis Ag | Bioconjugates of synthetic apelin polypeptides |
AP2016009021A0 (en) | 2013-07-25 | 2016-02-29 | Novartis Ag | Cyclic polypeptides for the treatment of heart failure |
JP6505692B2 (ja) | 2013-07-25 | 2019-04-24 | ノバルティス アーゲー | 心不全治療のためのジスルフィド環状ポリペプチド |
EP3024846A1 (en) | 2013-07-25 | 2016-06-01 | Novartis AG | Cyclic apelin derivatives for the treatment of heart failure |
US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
CN112851790A (zh) | 2014-06-23 | 2021-05-28 | 诺华股份有限公司 | 位点特异性蛋白质修饰 |
KR20170103970A (ko) * | 2015-01-23 | 2017-09-13 | 노파르티스 아게 | 개선된 반감기를 갖는 합성 아펠린 지방산 접합체 |
US10730911B2 (en) | 2015-04-08 | 2020-08-04 | Universitat Zurich | Backbone-cyclized peptidomimetics with GLP-1R modulating activity |
EP3416688B1 (en) | 2016-02-15 | 2022-08-17 | INSERM - Institut National de la Santé et de la Recherche Médicale | Apelin for use in the treatment of post-operative cognitive dysfunction |
JOP20190245A1 (ar) | 2017-04-20 | 2019-10-15 | Novartis Ag | أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط |
TW202327638A (zh) * | 2021-12-16 | 2023-07-16 | 加拿大商沙克普拉健康與人文科學公司 | 艾帕素激導性巨環化合物及其用途 |
Family Cites Families (119)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2951135A1 (de) | 1979-12-19 | 1981-06-25 | Hoechst Ag, 6230 Frankfurt | Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung |
US4889861A (en) | 1982-12-21 | 1989-12-26 | Ciba-Geigy Corp. | Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors |
US4617307A (en) | 1984-06-20 | 1986-10-14 | Ciba-Geigy Corporation | Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors |
DE3347565A1 (de) | 1983-12-30 | 1985-07-11 | Thomae Gmbh Dr K | Neue phenylessigsaeurederivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
JPS6354321A (ja) | 1985-03-27 | 1988-03-08 | Ajinomoto Co Inc | 血糖降下剤 |
US5120712A (en) | 1986-05-05 | 1992-06-09 | The General Hospital Corporation | Insulinotropic hormone |
US5118666A (en) | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
CA2073856C (en) | 1990-01-24 | 2002-12-03 | Douglas I. Buckley | Glp-1 analogs useful for diabetes treatment |
AU654331B2 (en) | 1991-03-30 | 1994-11-03 | Kissei Pharmaceutical Co. Ltd. | Succinic acid compounds |
US5155100A (en) | 1991-05-01 | 1992-10-13 | Ciba-Geigy Corporation | Phosphono/biaryl substituted dipeptide derivatives |
RU2086544C1 (ru) | 1991-06-13 | 1997-08-10 | Хоффманн-Ля Рош АГ | Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина |
JP2921982B2 (ja) | 1991-06-21 | 1999-07-19 | ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング | (s)(+)−2−エトキシ−4−[n−[1−(2−ピペリジノ−フェニル)−3−メチル−1−ブチル〕アミノカルボニルメチル〕−安息香酸、この化合物を含む医薬組成物及びその調製方法 |
DK0526171T3 (da) | 1991-07-30 | 1997-08-25 | Ajinomoto Kk | Krystaller af N-(trans-4-isopropylcyclohexylcarbonyl)-Dphenylalanin og fremgangsmåder til fremstilling deraf |
EP0618803A4 (en) | 1991-12-19 | 1995-03-22 | Southwest Found Biomed Res | POLYPEPTIDE INHIBITING PROTEIN TRANSFER TO CHOLESTERYL ESTERS, ANTIBODIES AGAINST SYNTHETIC POLYPEPTIDE AND ANTI-ATHEROSCLEROSIS PROPHYLACTIC AND THERAPEUTIC TREATMENTS. |
DK0630405T3 (da) | 1992-11-17 | 1999-01-04 | Icos Corp | Hidtil ukendt 7-transmembranreceptor benævnt V28 |
IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
US5705483A (en) | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
TW313568B (es) | 1994-12-20 | 1997-08-21 | Hoffmann La Roche | |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US6428771B1 (en) | 1995-05-15 | 2002-08-06 | Pharmaceutical Discovery Corporation | Method for drug delivery to the pulmonary system |
CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
DE19616486C5 (de) | 1996-04-25 | 2016-06-30 | Royalty Pharma Collection Trust | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
US20020052310A1 (en) | 1997-09-15 | 2002-05-02 | Massachusetts Institute Of Technology The Penn State Research Foundation | Particles for inhalation having sustained release properties |
TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
US6555339B1 (en) | 1997-04-14 | 2003-04-29 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human protein-coupled receptors |
CA2313246A1 (en) | 1997-12-24 | 1999-07-08 | Takeda Chemical Industries, Ltd. | Polypeptide, their production and use |
US6197786B1 (en) | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
GT199900147A (es) | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
AU5759399A (en) | 1998-09-25 | 2000-04-17 | Takeda Chemical Industries Ltd. | Peptide derivative |
ATE440857T1 (de) | 1998-10-05 | 2009-09-15 | Takeda Pharmaceutical | Verfahren zum eliminieren von n-terminalem methionin |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
CO5150173A1 (es) | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
US7045532B2 (en) | 1999-04-30 | 2006-05-16 | Millennium Pharmaceuticals, Inc. | ACE-2 modulating compounds and methods of use thereof |
US6521607B1 (en) | 1999-09-23 | 2003-02-18 | Pharmacia Corporation | (R)-chiral halogenated substituted N-phenoxy N-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity |
EP1270585B1 (en) | 2000-03-23 | 2006-05-17 | Takeda Chemical Industries, Ltd. | Peptide derivative |
JP2003530343A (ja) | 2000-04-12 | 2003-10-14 | ノバルティス アクチエンゲゼルシャフト | アルドステロンシンターゼインヒビター単体またはat1−レセプターアンタゴニストとの組み合わせの新規医薬使用 |
WO2001090123A2 (en) | 2000-05-23 | 2001-11-29 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the agtrl1 gene |
DK2322631T3 (en) | 2001-04-19 | 2015-01-12 | Scripps Research Inst | Methods and compositions for the production of orthogonal tRNA-aminoacyl-tRNA syntetasepar |
CA2453434C (en) | 2001-07-16 | 2009-04-14 | Hk Pharmaceuticals, Inc. | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions |
WO2003063892A1 (fr) | 2002-01-29 | 2003-08-07 | Takeda Chemical Industries, Ltd. | Utilisation d'apeline |
AU2003232941A1 (en) | 2002-06-07 | 2003-12-22 | Glaxo Group Limited | N-mercaptoacyl phenyalanine derivatives, process for their preparation, and pharmaceutical compositions containing them |
DE60307483T2 (de) | 2002-08-07 | 2007-07-05 | Novartis Ag | Organische verbindungen als mittel zur behandlung von aldosteronbedingten zuständen |
ES2305520T3 (es) | 2002-11-18 | 2008-11-01 | Novartis Ag | Derivados de imidazo(1,5a)piridina y metodos para tratar enfermedades mediadas por aldosterona. |
US7736646B2 (en) | 2003-03-12 | 2010-06-15 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods for modulating angiogenesis with apelin compositions |
US20050152836A1 (en) | 2003-05-22 | 2005-07-14 | Euan Ashley | Diagnostic markers and pharmacological targets in heart failure and related reagents and methods of use thereof |
US7947280B2 (en) | 2003-05-22 | 2011-05-24 | The Board Of Trustees Of The Leland Stanford Junior University | Apelin and uses thereof |
EP1520861A1 (en) | 2003-09-11 | 2005-04-06 | Aventis Pharma Deutschland GmbH | Test system for the identification of APJ receptor ligands |
WO2005037867A1 (en) | 2003-10-15 | 2005-04-28 | Pdl Biopharma, Inc. | ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG |
PL1732933T3 (pl) | 2004-03-26 | 2008-12-31 | Lilly Co Eli | Związki do leczenia dyslipidemii |
UA90269C2 (ru) | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
WO2005106493A1 (en) | 2004-04-30 | 2005-11-10 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled apelin receptor (apj) |
ATE490241T1 (de) | 2004-05-28 | 2010-12-15 | Novartis Ag | Heterocyclische verbindungen und deren verwendung als aldosteronsynthaseinhibitoren |
US7612088B2 (en) | 2004-05-28 | 2009-11-03 | Speedel Experimenta Ag | Heterocyclic compounds and their use as aldosterone synthase inhibitors |
AR049125A1 (es) | 2004-05-28 | 2006-06-28 | Speedel Experimenta Ag | Heterociclos biciclicos nitrogenados inhibidores de la aromatasa. |
CN101035756A (zh) | 2004-06-17 | 2007-09-12 | 南卡罗来纳州医科大学研究发展基金会 | 非天然氨基酸 |
WO2006005726A2 (en) | 2004-07-09 | 2006-01-19 | Speedel Experimenta Ag | Heterocyclic compounds |
US20060045880A1 (en) | 2004-08-23 | 2006-03-02 | Krieg Paul A | Methods for modulating angiogenesis and apoptosis with apelin compositions |
JP2008013436A (ja) | 2004-10-14 | 2008-01-24 | Kanazawa Univ | 血管形成促進剤 |
US20110097710A1 (en) | 2004-10-26 | 2011-04-28 | Macrae Calum A | Methods for detecting atrial fibrillation and related conditions |
US8431558B2 (en) | 2004-11-01 | 2013-04-30 | The Regents Of The University Of California | Compositions and methods for modification of biomolecules |
US20060159676A1 (en) | 2005-01-14 | 2006-07-20 | Krieg Paul A | Methods for modulating angiogenesis, lymphangiogenesis, and apoptosis with apelin compositions |
TW200716634A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
TW200716105A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Imidazole compounds |
EP2330125A3 (en) | 2005-08-11 | 2012-12-12 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
US8673848B2 (en) | 2012-01-27 | 2014-03-18 | Novartis Ag | Synthetic apelin mimetics for the treatment of heart failure |
AU2006294644A1 (en) * | 2005-09-27 | 2007-04-05 | Amunix, Inc. | Proteinaceous pharmaceuticals and uses thereof |
EP1876448A1 (en) | 2005-09-30 | 2008-01-09 | DIGILAB BioVisioN GmbH | Method and analytical reagents for identifying therapeutics using biomarkers responsive to thiazolidinediones. |
US7736346B2 (en) | 2005-10-18 | 2010-06-15 | Biocardia, Inc. | Bio-interventional therapeutic treatments for cardiovascular diseases |
TW200804378A (en) | 2005-12-09 | 2008-01-16 | Speedel Experimenta Ag | Organic compounds |
US20080031871A1 (en) | 2006-02-21 | 2008-02-07 | Allen Margaret L | Memory and learning impairments associated with disruption of Ephrin receptor A6 (EphA6) gene |
US20090156875A1 (en) | 2006-04-04 | 2009-06-18 | Takafumi Tomioka | Methane separation method, methane separation apparatus, and methane utilization system |
TW200808812A (en) | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
TW200808813A (en) | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
WO2007123233A1 (ja) | 2006-04-25 | 2007-11-01 | Kyushu University, National University Corporation | 動脈硬化性疾患関連遺伝子、およびその利用 |
MX2008014284A (es) | 2006-05-10 | 2008-11-18 | Novartis Ag | Derivados biciclicos como inhibidores de cetp. |
EP1886695A1 (en) | 2006-06-27 | 2008-02-13 | Speedel Experimenta AG | Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist |
JP5042311B2 (ja) | 2006-07-20 | 2012-10-03 | ノバルティス アーゲー | Cetp阻害剤としてのアミノピペリジン誘導体 |
JP2010501573A (ja) | 2006-08-25 | 2010-01-21 | ノバルティス アクチエンゲゼルシャフト | アルドステロン合成酵素および/または11−β−ヒドロキシラーゼおよび/またはアロマターゼが介在する疾患の処置のための縮合イミダゾール誘導体 |
US8436035B2 (en) | 2006-12-18 | 2013-05-07 | Novartis Ag | Organic compounds |
CN101605776A (zh) | 2006-12-18 | 2009-12-16 | 诺瓦提斯公司 | 4-咪唑基-1,2,3,4-四氢喹啉衍生物及其作为醛甾酮/11-β-羟化酶抑制剂的用途 |
US20100041722A1 (en) | 2006-12-18 | 2010-02-18 | Qi-Ying Hu | Organic compounds |
BRPI0809645A2 (pt) | 2007-03-29 | 2014-09-23 | Novartis Ag | Espoiro-composots heterocíclicos |
TWI448284B (zh) | 2007-04-24 | 2014-08-11 | Theravance Inc | 雙效抗高血壓劑 |
US7834041B2 (en) | 2007-09-07 | 2010-11-16 | Theravance, Inc. | Dual-acting antihypertensive agents |
CA2698824A1 (en) | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of peptide yy, alone or in combination with glucagon-like peptide, for use in medicine |
WO2009033819A2 (en) | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
KR101564793B1 (ko) | 2007-11-05 | 2015-10-30 | 노파르티스 아게 | 고지질혈증 또는 동맥경화증과 같은 질환의 치료에 유용한 cetp 억제제로서의 4-벤질아미노-1-카르복시아실-피페리딘 유도체 |
PT2229356E (pt) | 2007-12-03 | 2012-01-20 | Novartis Ag | Derivados de 4-benzilamino-pirrolidina 1,2-dissubstituídos como inibidores de cetp úteis para o tratamento de doenças tais como hiperlipidemia ou arteriosclerose |
US20110123534A1 (en) | 2007-12-12 | 2011-05-26 | Erasmus University Medical Center Rotterdam | Novel compounds for modulating neovascularisation and methods of treatment using these compounds |
WO2009075566A1 (en) | 2007-12-12 | 2009-06-18 | Erasmus University Medical Center Rotterdam | Biomarkers for cardiovascular disease |
WO2009134741A1 (en) | 2008-04-29 | 2009-11-05 | Theravance, Inc. | Dual-acting antihypertensive agents |
EP2303913A4 (en) * | 2008-06-20 | 2013-07-24 | Univ Texas | TARGETING PEPTIDES OF CRKL |
AR072297A1 (es) | 2008-06-27 | 2010-08-18 | Novartis Ag | Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona. |
CN102264697B (zh) | 2008-10-24 | 2015-09-09 | Irm责任有限公司 | 生物合成产生的吡咯啉-羧基-赖氨酸以及通过吡咯啉-羧基-赖氨酸和吡咯赖氨酸残基化学衍生化的位点特异性蛋白修饰 |
NZ592738A (en) | 2008-11-04 | 2013-01-25 | Anchor Therapeutics Inc | APJ receptor compounds attached to a lipophilic tether through a carbonyl linker |
WO2010115874A1 (en) | 2009-04-07 | 2010-10-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment and the diagnosis ofpulmonary arterial hypertension |
AU2010247414B2 (en) | 2009-05-15 | 2013-08-01 | Novartis Ag | Aryl pyridine as aldosterone synthase inhibitors |
AR076707A1 (es) | 2009-05-28 | 2011-06-29 | Novartis Ag | Derivados amino-propionicos sustituidos como inhibidores de neprilisina |
EP2435402B1 (en) | 2009-05-28 | 2016-04-13 | Novartis AG | Substituted aminobutyric derivatives as neprilysin inhibitors |
EP2496243A2 (en) | 2009-11-04 | 2012-09-12 | Erasmus University Medical Center Rotterdam | Novel compounds for modulating neovascularisation and methods of treatment using these compounds |
JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
US9782454B2 (en) | 2010-04-22 | 2017-10-10 | Longevity Biotech, Inc. | Highly active polypeptides and methods of making and using the same |
TW201138808A (en) | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
RU2457216C1 (ru) | 2010-12-21 | 2012-07-27 | Федеральное государственное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития Российской Федерации (ФГУ "РКНПК" Минздравсоцразвития России) | Додекапептиды, обладающие кардиопротекторными свойствами |
LT3045183T (lt) | 2011-03-11 | 2018-10-25 | Genzyme Corporation | Pegiliuotas apelinas ir jo panaudojimas |
CU23950B1 (es) * | 2011-03-21 | 2013-10-29 | Ct De Ingeniería Genética Y Biotecnología | Péptidos cíclicos con actividad antineoplásica y antiangiogénica |
CA2840944A1 (en) * | 2011-07-08 | 2013-01-17 | Bayer Intellectual Property Gmbh | Fusion proteins releasing relaxin and uses thereof |
CN104254540A (zh) | 2012-01-09 | 2014-12-31 | 安科治疗公司 | Apj受体化合物 |
US8921307B2 (en) | 2012-11-20 | 2014-12-30 | Novartis Ag | Synthetic linear apelin mimetics for the treatment of heart failure |
US10022256B2 (en) * | 2012-11-30 | 2018-07-17 | Novartis Ag | Methods for making conjugates from disulfide-containing proteins |
EP2935311B1 (en) | 2012-12-20 | 2021-03-31 | Amgen Inc. | Apj receptor agonists and uses thereof |
BR112015020587A2 (pt) | 2013-03-14 | 2017-10-10 | Regeneron Pharma | proteínas de fusão de apelina e suas utilizações |
AP2016009021A0 (en) | 2013-07-25 | 2016-02-29 | Novartis Ag | Cyclic polypeptides for the treatment of heart failure |
SG11201600208RA (en) | 2013-07-25 | 2016-02-26 | Novartis Ag | Bioconjugates of synthetic apelin polypeptides |
EP3024846A1 (en) | 2013-07-25 | 2016-06-01 | Novartis AG | Cyclic apelin derivatives for the treatment of heart failure |
JP6505692B2 (ja) | 2013-07-25 | 2019-04-24 | ノバルティス アーゲー | 心不全治療のためのジスルフィド環状ポリペプチド |
-
2014
- 2014-07-21 AP AP2016009021A patent/AP2016009021A0/en unknown
- 2014-07-21 BR BR112016001542A patent/BR112016001542A2/pt not_active Application Discontinuation
- 2014-07-21 UY UY35670A patent/UY35670A/es not_active Application Discontinuation
- 2014-07-21 CN CN201480052591.5A patent/CN105612172A/zh active Pending
- 2014-07-21 US US14/336,262 patent/US9266925B2/en not_active Expired - Fee Related
- 2014-07-21 MX MX2016001020A patent/MX2016001020A/es unknown
- 2014-07-21 TN TN2016000031A patent/TN2016000031A1/en unknown
- 2014-07-21 SG SG11201600211XA patent/SG11201600211XA/en unknown
- 2014-07-21 EP EP14747284.9A patent/EP3024845A1/en not_active Withdrawn
- 2014-07-21 TW TW103124998A patent/TW201536814A/zh unknown
- 2014-07-21 EA EA201690278A patent/EA201690278A1/ru unknown
- 2014-07-21 JP JP2016529807A patent/JP6501775B2/ja not_active Expired - Fee Related
- 2014-07-21 PE PE2016000106A patent/PE20160878A1/es not_active Application Discontinuation
- 2014-07-21 KR KR1020167004512A patent/KR20160031551A/ko not_active Application Discontinuation
- 2014-07-21 WO PCT/US2014/047377 patent/WO2015013168A1/en active Application Filing
- 2014-07-21 CA CA2918074A patent/CA2918074A1/en not_active Withdrawn
- 2014-07-21 AU AU2014293386A patent/AU2014293386B2/en not_active Revoked
-
2015
- 2015-12-09 US US14/963,391 patent/US9683019B2/en not_active Expired - Fee Related
-
2016
- 2016-01-15 PH PH12016500104A patent/PH12016500104A1/en unknown
- 2016-01-19 IL IL243682A patent/IL243682A0/en unknown
- 2016-01-25 CL CL2016000190A patent/CL2016000190A1/es unknown
- 2016-01-25 SV SV2016005145A patent/SV2016005145A/es unknown
- 2016-01-25 CU CUP2016000013A patent/CU20160013A7/es unknown
- 2016-01-25 CR CR20160048A patent/CR20160048A/es unknown
- 2016-06-01 HK HK16106224.7A patent/HK1218298A1/zh unknown
-
2017
- 2017-04-25 US US15/497,135 patent/US20170233443A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
HK1218298A1 (zh) | 2017-02-10 |
JP2016532681A (ja) | 2016-10-20 |
SG11201600211XA (en) | 2016-02-26 |
CR20160048A (es) | 2016-06-17 |
AU2014293386A1 (en) | 2016-02-11 |
US20160108091A1 (en) | 2016-04-21 |
AP2016009021A0 (en) | 2016-02-29 |
WO2015013168A1 (en) | 2015-01-29 |
EA201690278A1 (ru) | 2016-06-30 |
PH12016500104A1 (en) | 2016-04-18 |
US20170233443A1 (en) | 2017-08-17 |
SV2016005145A (es) | 2016-11-21 |
JP6501775B2 (ja) | 2019-04-17 |
TN2016000031A1 (en) | 2017-07-05 |
KR20160031551A (ko) | 2016-03-22 |
UY35670A (es) | 2015-02-27 |
CN105612172A (zh) | 2016-05-25 |
PE20160878A1 (es) | 2016-09-08 |
CU20160013A7 (es) | 2016-08-31 |
AU2014293386B2 (en) | 2016-11-17 |
TW201536814A (zh) | 2015-10-01 |
US20150031604A1 (en) | 2015-01-29 |
MX2016001020A (es) | 2016-08-03 |
US9266925B2 (en) | 2016-02-23 |
IL243682A0 (en) | 2016-04-21 |
BR112016001542A2 (pt) | 2017-08-29 |
EP3024845A1 (en) | 2016-06-01 |
CA2918074A1 (en) | 2015-01-29 |
US9683019B2 (en) | 2017-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2016000190A1 (es) | Polipéptidos cíclicos para el tratamiento de la insuficiencia cardiaca. | |
DK3668562T3 (da) | Blodpumpe | |
DK3432944T3 (da) | Blodpumpe | |
DK3359214T3 (da) | Blodpumpe | |
CO7020879A2 (es) | Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardíaca | |
DK3795208T3 (da) | Blodpumpe | |
DK3310902T3 (da) | Kontinuerligt, bioprintet flerlagsvævsstruktur | |
DK3229810T3 (da) | Phospholipid-ether-analoger som kræftrammende lægemiddelvehikler | |
DK3069738T3 (da) | Blodpumpe | |
DK3069740T3 (da) | Blodpumpe | |
DK3261589T3 (da) | Lagdelte medicinske indretninger | |
DK3104854T3 (da) | Mast-celle-stabilisatorer til lungesygdomsbehandling | |
DK2764881T3 (da) | System til medicinsk behandling | |
DK3131497T3 (da) | Instrumenter til anvendelse med implanterbare indkapslingsindretninger | |
FR3007989B1 (fr) | Autoinjecteur. | |
DK3294283T3 (da) | Sacubitril-valsartan-doseringsregime til behandling af hjerteinsufficiens | |
FR3013601B1 (fr) | Autoinjecteur. | |
DE112017004905A5 (de) | Blutpumpe | |
DK3337353T3 (da) | Stol | |
DK3474803T3 (da) | Medicinsk forbinding | |
DK3188599T3 (da) | Medicinske behandlinger baseret på anamorelin | |
ES1102512Y (es) | Dispositivo para la aplicacion de acciones terapeuticas sobre el cuerpo. | |
FI20145982A (fi) | Potilasalusta | |
ES1078864Y (es) | Carpeta-silla transportable. | |
FI20165859A (fi) | Runkorakenne |